GADD45B and plasma cell myeloma: We therefore developed the D-tripeptide inhibitor of the GADD45β/MKK7 complex, DTP3, which effectively disrupts this complex at nanomolar concentrations, in vitro, by binding to MKK7, and as a result, selectively kills multiple myeloma cells by inducing MKK7/JNK-dependent apoptosis, without toxicity to normal tissues [200,201].